Key Publications July 14, 2017

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

Am Heart J. 2017;186:73-82

Sharma A, de Souza Brito F, Sun JL, Thomas L, Haffner S, Holman RR, Lopes RD